Equillium, Inc. — Form 8-K
Filed October 26, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Equillium announced first-subject dosing in its Phase 1 clinical trial of EQ504 (oral AhR modulator for inflammatory diseases) in Australia. The milestone triggered a $20 million funding closing under a prior August 2025 equity private placement agreement: 14,957,260 common shares at $0.57/share plus 20,130,457 pre-funded warrants at $0.5669/warrant for ~$20M gross proceeds. Total placement now reaches $50M; cash runway expected to fund operations into 2029. Phase 1 topline data anticipated Q2 2027; proof-of-concept study in ulcerative colitis patients targeted for H2 2027.
Why this rating
Milestone funding ($20M) is 281% of company market cap ($7.1M), ensuring 2+ years runway for clinical advancement—critical for pre-revenue biotech. First-subject dosing validates program execution and de-risks near-term operations, but clinical success remains uncertain.
Price action (we called it positive)
before filing · preread $1.29 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.